Arsia Therapeutics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$78.2M
Arsia Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to develop innovative protein formulation. The company produces concentrated drugs and related products with low viscosity, suitable for small-volume subcutaneous injection, enabling clients to avail improved access to highly viscous protein therapeutics.
Contact Information
Website
www.arsiarx.comCorporate Office
- Kendall Square
- Cambridge, MA
- United States
Corporate Office
- Kendall Square
- Cambridge, MA
- United States
Arsia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 16-Nov-2016 | $78.2M | Completed | Generating Revenue | ||
| 3. Early Stage VC | 01-Jan-2015 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
Arsia Therapeutics Comparisons
Industry
Financing
Details
Arsia Therapeutics Competitors (21)
One of Arsia Therapeutics’s 21 competitors is RheoSense Inc., a Corporation company based in San Ramon, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| RheoSense Inc. | Corporation | San Ramon, CA | ||||
| Antibody Production Services | Corporation | Hertfordshire, United Kingdom | ||||
| Domainex | Venture Capital-Backed | Saffron Walden, United Kingdom | ||||
| Agrisera | Formerly PE-Backed | Vannas, Sweden | ||||
| Protein Ark | Private Equity-Backed | Rotherham, United Kingdom |
Arsia Therapeutics Patents
Arsia Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2016054259-A1 | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents | Inactive | 01-Oct-2014 | ||
| WO-2015038811-A2 | Liquid protein formulations containing ionic liquids | Inactive | 11-Sep-2013 | ||
| WO-2015038811-A3 | Liquid protein formulations containing ionic liquids | Inactive | 11-Sep-2013 | ||
| WO-2015038782-A1 | Liquid protein formulations containing organophosphates | Inactive | 11-Sep-2013 | ||
| WO-2015038818-A2 | Liquid protein formulations containing viscosity-lowering agents | Inactive | 11-Sep-2013 | A61K47/06 |
Arsia Therapeutics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | |||
| LabCentral | Accelerator/Incubator | |||
| Polaris Partners | Venture Capital | Minority |
Arsia Therapeutics FAQs
-
When was Arsia Therapeutics founded?
Arsia Therapeutics was founded in 2013.
-
Where is Arsia Therapeutics headquartered?
Arsia Therapeutics is headquartered in Cambridge, MA.
-
What industry is Arsia Therapeutics in?
Arsia Therapeutics’s primary industry is Drug Delivery.
-
Is Arsia Therapeutics a private or public company?
Arsia Therapeutics is a Private company.
-
What is the current valuation of Arsia Therapeutics?
The current valuation of Arsia Therapeutics is .
-
What is Arsia Therapeutics’s current revenue?
The current revenue for Arsia Therapeutics is .
-
Who are Arsia Therapeutics’s investors?
Johnson & Johnson Innovation - JLABS, LabCentral, and Polaris Partners have invested in Arsia Therapeutics.
-
Who are Arsia Therapeutics’s competitors?
RheoSense Inc., Antibody Production Services, Domainex, Agrisera, and Protein Ark are some of the 21 competitors of Arsia Therapeutics.
-
When was Arsia Therapeutics acquired?
Arsia Therapeutics was acquired on 16-Nov-2016.
-
Who acquired Arsia Therapeutics?
Arsia Therapeutics was acquired by Eagle Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process